Cyclooxygenase-2 Inhibitors Attenuate Increased Blood Pressure in Renovascular Hypertensive Models, but Not in Deoxycorticosterone-Salt Hypertension.

  • OKUMURA Toshiaki
    Department of Internal Medicine, Kitasato University School of Medicine
  • HAYASHI Izumi
    Department of Pharmacology, Kitasato University School of Medicine Department of Molecular Pharmacology, Molecular Medical Biology, Kitasato University Graduate School of Medical Sciences
  • IKEZAWA Tomoaki
    Department of Internal Medicine, Kitasato University School of Medicine
  • YAMANAKA Mariko
    Department of Internal Medicine, Kitasato University School of Medicine
  • TAKATA Tesshu
    Department of Internal Medicine, Kitasato University School of Medicine
  • FUJITA Yoshikuni
    Department of Internal Medicine, Kitasato University School of Medicine
  • SAIGENJI Katsunori
    Department of Internal Medicine, Kitasato University School of Medicine
  • YAMASHINA Shohei
    Department of Anatomy, Kitasato University School of Medicine
  • MAJIMA Masataka
    Department of Pharmacology, Kitasato University School of Medicine Department of Molecular Pharmacology, Molecular Medical Biology, Kitasato University Graduate School of Medical Sciences

書誌事項

公開日
2002
資源種別
journal article
DOI
  • 10.1291/hypres.25.927
公開者
日本高血圧学会

この論文をさがす

説明

COX-2 is an inducible cyclooxygenase (COX) that has been reported to be expressed in the macula densa and surrounding cortical thick ascending limb in normotensive rats. The present study assessed the contribution of COX-2 in three different rat models of hypertension, each characterized by a different activation of the renal renin-angiotensin system. Mean blood pressure (MBP) in the rat 2 kidney-1 clip (2K1C) model was significantly reduced with a COX-2 selective inhibitor, NS-398 (10 mg/kg, p.o., twice a day) (vehicle-administered rats (n =8): 154±6 mmHg; NS-398-administered rats (n =5): 128±10 mmHg). By contrast, a COX-1 selective inhibitor, mofezolac, did not lower MBP. Increased plasma renin activity (23±8 ng/kg/h (n =6) vs. sham operation, 2.4±0.9 ng/kg/h (n =4)) was markedly reduced to 6.8±2.7 ng/ml/h (n =5) by NS-398, but not by mofezolac. The development of 1 kidney-1 clip (1K1C) hypertension was also inhibited by NS-398 (vehicle (n =12): 133±1 mmHg; NS-398 (n =7): 122±3 mmHg) accompanied by a reduction in plasma renin activity (3.0±0.3 ng/ml/h, n =4) to 1.0±0.2 ng/ml/h (n =5). The COX-2 inhibitor increased urinary excretions in the 1K1C model, but not in the 2K1C model. In a deoxycorticosterone acetate (DOCA)-salt model, plasma renin activity was markedly suppressed to less than 0.3 ng/ml/h. The COX-2 inhibitor caused no significant changes in MBP, plasma renin activity, or urinary excretion, suggesting that COX-2 made a lesser contribution in this model. Increased expression of COX-2 mRNA and protein was observed in the kidneys of 1K1C and 2K1C rats, but not in DOCA-salt rats. These results suggest that COX-2 plays a significant role in the development of 2K1C and 1K1C renovascular hypertension, in addition to making a substantial contribution to the diuretic effect in the 1 K1C model. (Hypertens Res 2002; 25: 927-938)

収録刊行物

被引用文献 (3)*注記

もっと見る

参考文献 (84)*注記

もっと見る

詳細情報 詳細情報について

  • CRID
    1390282679697594880
  • NII論文ID
    10010315498
  • NII書誌ID
    AA10847079
  • DOI
    10.1291/hypres.25.927
  • COI
    1:CAS:528:DC%2BD3sXhtVGjsLo%3D
  • ISSN
    13484214
    09169636
    https://id.crossref.org/issn/09169636
  • PubMed
    12484518
  • Web Site
    https://search.jamas.or.jp/link/ui/2003113104
  • 本文言語コード
    en
  • 資料種別
    journal article
  • データソース種別
    • JaLC
    • Crossref
    • PubMed
    • CiNii Articles
    • OpenAIRE
  • 抄録ライセンスフラグ
    使用不可

問題の指摘

ページトップへ